Lumeva · MIG · Brazil · Headache specialist · captured by Luis Ortega on 14 Feb 2026 · reviewed by Dr. Priya Raman on 19 Feb 2026
Marked as duplicate
Verbatim as captured; never edited
Headache specialist at Hospital Sírio-Libanês raised dosing in hepatic impairment during a advisory board. They indicated this influences their current prescribing approach.
Human-approved by Dr. Priya Raman on 19 Feb 2026
Dosing in hepatic impairment: request for data reported by headache specialist (BR).
No AI assistance
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 2 | 20% | 8.0 |
| Strategic alignment | 3 | 20% | 12.0 |
| Scientific importance | 5 | 15% | 15.0 |
| Urgency | 3 | 15% | 9.0 |
| Novelty | 5 | 10% | 10.0 |
| Actionability | 1 | 10% | 2.0 |
| Confidence | 5 | 5% | 5.0 |
| Breadth of occurrence | 4 | 5% | 4.0 |
| Total | High 65 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
12 Feb 2026 · Dr. Tomoko Quinn, Hospital Sírio-Libanês · MSL Luis Ortega
Insight
Reviewed 19 Feb 2026 by Dr. Priya Raman
Action
Initiative
Decision
Outcome
Closure
Shared with Clinical Development; no further action required.
Duplicate of INS-0039 — Interest in IIS on lumevarin in chronic migraine with medication-overuse headache; population under-represented in trials.